Clinical Trials Logo

Clinical Trial Summary

The goal of this bridging study is to assess the safety and immunogenicity of BARYCELA inj. in healthy Vietnamese children aged between 12 months to 12 years. The main questions it aims to answer are: - Safety of BARYCELA inj. (Live attenuated varicella vaccine for injection) - Immunogenicity of BARYCELA inj. (Live attenuated varicella vaccine for injection) Participants will be administered subcutaneously with a single dose(0.5 mL dose) of the BARYCELA inj.(MG1111) on the upper arm (brachia lateral).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05664152
Study type Interventional
Source GC Biopharma Corp
Contact
Status Not yet recruiting
Phase N/A
Start date February 2023
Completion date June 2023

See also
  Status Clinical Trial Phase
Completed NCT01682109 - Palatability Testing of a New Paediatric Formulation of Valacyclovir Phase 4
Recruiting NCT05198570 - Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
Not yet recruiting NCT06409494 - Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years Phase 1
Recruiting NCT05604911 - Herpes Virus Infections in Kidney Transplant Patients
Recruiting NCT05532540 - Herpesvirus Immunology in Solid Organ Transplant Recipients - Liver Transplant Study
Completed NCT01689285 - Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir Phase 1
Terminated NCT04081480 - Pharmacokinetics of Valacyclovir Oral Solution in Children N/A
Recruiting NCT04403139 - VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination Phase 4